Cullinan Oncology, Inc. (NASDAQ:CGEM) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC increased its position in Cullinan Oncology, Inc. (NASDAQ:CGEM) by 12.3% during the fourth quarter, HoldingsChannel.com reports. The fund owned 14,449 shares of the company’s stock after acquiring an additional 1,587 shares during the quarter. SG Americas Securities LLC’s holdings in Cullinan Oncology were worth $147,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Nuveen Asset Management LLC grew its holdings in shares of Cullinan Oncology by 1.3% in the 3rd quarter. Nuveen Asset Management LLC now owns 107,360 shares of the company’s stock worth $1,376,000 after acquiring an additional 1,347 shares during the period. Rhumbline Advisers grew its holdings in shares of Cullinan Oncology by 4.7% in the 1st quarter. Rhumbline Advisers now owns 32,045 shares of the company’s stock worth $336,000 after acquiring an additional 1,445 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Cullinan Oncology by 5.6% in the 4th quarter. Alliancebernstein L.P. now owns 28,200 shares of the company’s stock worth $298,000 after acquiring an additional 1,500 shares during the period. California State Teachers Retirement System grew its holdings in shares of Cullinan Oncology by 7.9% in the 2nd quarter. California State Teachers Retirement System now owns 23,485 shares of the company’s stock worth $253,000 after acquiring an additional 1,719 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Cullinan Oncology by 15.9% in the 3rd quarter. Price T Rowe Associates Inc. MD now owns 13,617 shares of the company’s stock worth $175,000 after acquiring an additional 1,871 shares during the period. Institutional investors and hedge funds own 86.31% of the company’s stock.

Cullinan Oncology Stock Up 4.7 %

Shares of Cullinan Oncology stock opened at $17.32 on Wednesday. The firm has a market cap of $745.97 million, a PE ratio of -4.69 and a beta of 0.33. The business’s fifty day moving average is $17.30 and its two-hundred day moving average is $12.53. Cullinan Oncology, Inc. has a fifty-two week low of $7.64 and a fifty-two week high of $20.62.

Cullinan Oncology (NASDAQ:CGEM) last announced its quarterly earnings results on Thursday, March 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.42. Equities research analysts anticipate that Cullinan Oncology, Inc. will post -3.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CGEM. HC Wainwright lowered their price target on Cullinan Oncology from $34.00 to $29.00 and set a “buy” rating on the stock in a report on Tuesday. William Blair began coverage on Cullinan Oncology in a research note on Monday. They issued an “outperform” rating on the stock. Finally, Wedbush began coverage on Cullinan Oncology in a research note on Thursday, February 15th. They issued an “outperform” rating and a $30.00 target price on the stock. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $27.00.

Insider Activity at Cullinan Oncology

In related news, insider Corrine Savill sold 40,000 shares of the stock in a transaction on Monday, January 29th. The stock was sold at an average price of $14.09, for a total value of $563,600.00. Following the completion of the sale, the insider now directly owns 165,990 shares in the company, valued at approximately $2,338,799.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last three months, insiders sold 98,684 shares of company stock worth $1,437,624. Corporate insiders own 8.82% of the company’s stock.

About Cullinan Oncology

Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.